At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
In Brief
A Phase 2 clinical trial evaluating SEL, FIR, and 4 other interventions for Nonalcoholic Steatohepatitis. Completed, enrolled 395 participants across 101 sites in 6 countries.
Detailed Summary
The primary objectives of this study are: * To assess the safety and tolerability of selonsertib (SEL), firsocostat (FIR) and cilofexor (CILO), administered alone or in combination, in participants with bridging fibrosis or compensated cirrhosis due to NASH * To evaluate changes in liver fibrosis, without worsening of NASH
Study Details
Timeline
Interventions
18 mg tablet administered orally once daily without regard to food
20 mg tablet administered orally once daily without regard to food
30 mg tablet administered orally once daily without regard to food
Tablet administered orally once daily without regard to food
Tablet administered orally once daily without regard to food
Tablet administered orally once daily without regard to food